CO6270359A2 - Moduladores de piperidinil y piperazinil de y-secretasa - Google Patents

Moduladores de piperidinil y piperazinil de y-secretasa

Info

Publication number
CO6270359A2
CO6270359A2 CO10051578A CO10051578A CO6270359A2 CO 6270359 A2 CO6270359 A2 CO 6270359A2 CO 10051578 A CO10051578 A CO 10051578A CO 10051578 A CO10051578 A CO 10051578A CO 6270359 A2 CO6270359 A2 CO 6270359A2
Authority
CO
Colombia
Prior art keywords
secretasa
piperidinil
piperazinil
modulators
compounds
Prior art date
Application number
CO10051578A
Other languages
English (en)
Inventor
Chih Yung Ho
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6270359A2 publication Critical patent/CO6270359A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con los compuestos de Formula (I) como se describe en la presente, en donde las definiciones de Het, R0, R1, R2, R3, R4, R5, R6, R7, R8 y R9 se proporcionan en la descripcion. Los compuestos de formula (I) son ·tiles para el tratamiento de enfermedades asociadas con la actividad de γ-secretasa, que incluye la enfermedad de Alzheimer.
CO10051578A 2007-10-19 2010-04-30 Moduladores de piperidinil y piperazinil de y-secretasa CO6270359A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98118907P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6270359A2 true CO6270359A2 (es) 2011-04-20

Family

ID=40090456

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10051578A CO6270359A2 (es) 2007-10-19 2010-04-30 Moduladores de piperidinil y piperazinil de y-secretasa

Country Status (19)

Country Link
US (1) US8252935B2 (es)
EP (1) EP2212287B1 (es)
JP (1) JP5439381B2 (es)
KR (1) KR101569391B1 (es)
CN (1) CN101903347B (es)
AT (1) ATE543799T1 (es)
AU (1) AU2008312612B2 (es)
BR (1) BRPI0817433A2 (es)
CA (1) CA2702837A1 (es)
CO (1) CO6270359A2 (es)
CR (1) CR11447A (es)
EA (1) EA017119B1 (es)
ES (1) ES2378594T3 (es)
IL (1) IL205045A (es)
MX (1) MX2010004309A (es)
NI (1) NI201000064A (es)
NZ (1) NZ584716A (es)
WO (1) WO2009052126A1 (es)
ZA (1) ZA201003519B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5543354B2 (ja) 2007-10-19 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのアミン結合調節物質
EP2215043B1 (en) 2007-10-19 2013-03-06 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
EA017119B1 (ru) 2007-10-19 2012-09-28 Янссен Фармацевтика, Н.В. МОДУЛЯТОРЫ АКТИВНОСТИ γ-СЕКРЕТАЗЫ ИЗ ГРУППЫ ПИПЕРИДИНИЛА И ПИПЕРАЗИНИЛА
WO2011009064A1 (en) * 2009-07-17 2011-01-20 The J. David Gladstone Institutes Methods of controlling cell proliferation
EP2455370A1 (en) 2009-07-17 2012-05-23 Shionogi&Co., Ltd. Pharmaceutical product containing lactam or benzene sulfonamide compound
US8586776B2 (en) 2009-11-05 2013-11-19 Fibrostatin, S.L. GPBP inhibition using Q2 peptidomimetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2212287A (en) * 1938-09-13 1940-08-20 William S Stateler Milk bottle holder
BE790287A (fr) * 1971-10-28 1973-04-19 Delalande Sa Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
BE826017R (fr) 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
US4252951A (en) 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US5391817A (en) 1993-12-21 1995-02-21 Bristol-Myers Squibb Biaryl phospholipase A2 inhibitors
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5416187A (en) * 1994-04-04 1995-05-16 Eastman Chemical Company Process for the preparation of phenol-functional polyester resins
CA2406383A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
JP2007531742A (ja) * 2004-04-05 2007-11-08 シェーリング　コーポレイション 新規のγセクレターゼインヒビター
WO2005110963A1 (en) 2004-05-19 2005-11-24 Cellzome Ag (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy
US20080313061A1 (en) 2004-06-30 2008-12-18 Paysetter Pte Ltd System and Method for Facilitating Transfer of Physical Money and/or Credit
MX2007000040A (es) * 2004-06-30 2007-03-07 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas.
DE102004033876B4 (de) 2004-07-13 2009-01-15 Christoph Kaesbohrer Dreidimensionales Struktursystem
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
ATE445586T1 (de) 2006-04-21 2009-10-15 Cellzome Ltd Terphenylderivate zur alzheimerbehandlung
PT1849762E (pt) 2006-04-21 2009-09-16 Cellzome Ltd Ácidos bifenilcarboxílicos substituídos e seus derivados
MX2008015638A (es) * 2006-06-09 2009-01-09 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
CN101861297B (zh) 2007-10-17 2014-04-23 詹森药业有限公司 联苯羧酸及其衍生物
EP2215043B1 (en) 2007-10-19 2013-03-06 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
EA017119B1 (ru) 2007-10-19 2012-09-28 Янссен Фармацевтика, Н.В. МОДУЛЯТОРЫ АКТИВНОСТИ γ-СЕКРЕТАЗЫ ИЗ ГРУППЫ ПИПЕРИДИНИЛА И ПИПЕРАЗИНИЛА
JP5543354B2 (ja) 2007-10-19 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのアミン結合調節物質
JP2011500720A (ja) 2007-10-19 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｇｓｍ中間体
AU2008312653B2 (en) 2007-10-19 2013-03-07 Janssen Pharmaceutica, N.V. Amide linked modulators of y-secretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase

Also Published As

Publication number Publication date
AU2008312612A8 (en) 2010-05-27
ZA201003519B (en) 2012-07-25
CN101903347B (zh) 2013-03-27
NZ584716A (en) 2011-12-22
EP2212287B1 (en) 2012-02-01
JP2011500700A (ja) 2011-01-06
IL205045A0 (en) 2010-11-30
AU2008312612B2 (en) 2013-11-28
AU2008312612A2 (en) 2010-07-22
NI201000064A (es) 2010-09-13
KR101569391B1 (ko) 2015-11-16
ATE543799T1 (de) 2012-02-15
KR20100083829A (ko) 2010-07-22
CR11447A (es) 2011-01-14
MX2010004309A (es) 2010-05-03
AU2008312612A1 (en) 2009-04-23
CA2702837A1 (en) 2009-04-23
US8252935B2 (en) 2012-08-28
EP2212287A1 (en) 2010-08-04
EA201070495A1 (ru) 2010-10-29
ES2378594T8 (es) 2013-02-27
IL205045A (en) 2015-08-31
US20090105275A1 (en) 2009-04-23
JP5439381B2 (ja) 2014-03-12
BRPI0817433A2 (pt) 2015-06-16
WO2009052126A1 (en) 2009-04-23
EA017119B1 (ru) 2012-09-28
CN101903347A (zh) 2010-12-01
ES2378594T3 (es) 2012-04-16

Similar Documents

Publication Publication Date Title
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MY151348A (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
CR11447A (es) Moduladores de piperidinil y piperazinil de y secretasa
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
EA200700707A1 (ru) Производные 2-ациламинотиазола
MX2010004308A (es) Moduladores enlazados a amida gamma secretasa.
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
UY32002A (es) Piridinilo moduladores de gamma-secretasa
EA201070497A1 (ru) Промежуточные продукты мгс
EA201070498A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
FC Application refused